<DOC>
	<DOCNO>NCT01147484</DOCNO>
	<brief_summary>The purpose study find effect new drug foretinib type breast cancer , call `` triple negative '' breast cancer cancer tissue estrogen , progesterone HER2 receptor negative .</brief_summary>
	<brief_title>A Study Foretinib Patients With Recurrent/Metastatic Breast Cancer</brief_title>
	<detailed_description>This research do treatment cure type cancer . Although type chemotherapy cause cancer shrink time , good option need .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis invasive breast cancer , estrogen receptor ( ER ) negative , progesterone receptor ( PR ) negative human epidermal growth factor receptor 2 ( HER2 ) negative . Formalin fix paraffin embed tissue available central pathology review translational study . Patients enter second stage accrual must accessible tumour lesion biopsy . Advanced recurrent/ metastatic disease incurable standard therapy . Clinically and/or radiologically document measurable disease . At least one site disease must unidimensionally measurable . ECOG performance 0 , 1 2 . Age ≥ 18 year age . Previous Therapy : Any treatmentrelated major organ toxicity must recover ≤ grade 1 . Patients may receive adjuvant chemotherapy and/or one prior line chemotherapy recurrent/metastatic setting . A minimum 21 day since last dose chemotherapy must elapse prior registration . No prior therapy cMet inhibitor angiogenesis inhibitor . Other targeted agent permissible provide minimum 21 day elapse since last day target therapy registration . Prior radiation therapy permit provided patient recover acute toxic effect radiation therapy prior registration , least 21 day elapse day last fraction radiation date registration . Exceptions may make nonmyelosuppressive radiation peripheral area . Previous surgery permit provide wound heal occur least 14 day elapse surgery major . Granulocytes ( AGC ) ≥ 1.5 x 109/L ; Platelets ≥ 100 x 109/L Serum creatinine ≤ 1.2 x UNL ; Total bilirubin ≤ 1.2 x UNL ; ALT AST ≤ 2 x UNL Women must post menopausal , surgically sterile use reliable form contraception study 90 day discontinue therapy . Women childbearing potential must pregnancy test take proven negative within 7 day prior registration must lactate . Patients require oral anticoagulant ( coumadin , warfarin ) eligible Patient consent must obtain accord local Institutional and/or University Human Experimentation Committee requirement . Protocol treatment must begin within 7 work day patient registration . History malignancy , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumour curatively treat evidence disease ≥ 5 year . Resting BP consistently high systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ( presence absence stable dose antihypertensive medication ) poorly control hypertension , history labile hypertension poor compliance antihypertensive medication . Appreciable cavitating actively bleed lesion . Untreated brain meningeal metastasis . ( Patients neurologically stable treat brain metastasis discontinue corticosteroid least two week prior study registration evidence cavitation hemorrhage eligible ) . Untreated and/or uncontrolled cardiovascular condition and/or symptomatic cardiac dysfunction . Patients significant cardiac history ( even control ) prior anthracycline exposure require LVEF &gt; 50 % . GI tract disease result inability absorb oral medication . Active uncontrolled infection , serious illness medical condition would permit patient manage accord protocol . Known hypersensitivity study drug component . Potent CYP3A4 inhibitors/inducers ( e.g . ketoconazole , carbamazepine ) must discontinue least 7 day prior Day 1 , Cycle 1 . Treatment , concurrent within 3 week prior registration , investigational drug anticancer therapy . Proliferative diabetic retinopathy , retinal arteritis hemorrhage . History pulmonary embolus deep vein thrombosis diagnose and/or treat within 6 month prior registration .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>